Join the 'Thrombocytopenia' group to help and get support from people like you.
Posted 20 Nov 2012 by Drugs.com
LONDON, Nov. 19, 2012 – GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Promacta for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. Promacta is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. Promacta in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure. There are limitations to the use of Promacta in patients suffering from chronic hepatitis C-associated thrombocytopenia. These include: Promacta should not be used in an attempt to normalize platelet counts; Promacta should be used only in patients with ch ... Read more
Ask a Question
Related Condition Support Groups
Related Drug Support Groups
prednisone, dexamethasone, Decadron, Sterapred, Deltasone, Sterapred DS, Adrenocot, Cerezyme, Promacta, view more... Liquid Pred, eltrombopag, Meticorten, Dexpak Taperpak, Medidex LA, Prednicot, Dalalone, Decaject, Baycadron, Medidex, Prednicen-M, Orasone, Dexone, Solurex LA, Dexacen-4, Decadron-LA, Hexadrol, imiglucerase, Solurex, De-Sone LA, Dexone LA, Primethasone, Dexasone LA, Dexasone, Dexacort-LA, Dexacorten